Portal de Periódicos da CAPES

Endocytosis pathways in endothelium: how many?

2006; American Physical Society; Volume: 290; Issue: 5 Linguagem: Inglês

10.1152/ajplung.00533.2005

1522-1504

Radu V. Stan,

Erythrocyte Function and Pathophysiology

EDITORIAL FOCUSEndocytosis pathways in endothelium: how many?Radu V. StanRadu V. StanPublished Online:01 May 2006https://doi.org/10.1152/ajplung.00533.2005MoreFiguresReferencesRelatedInformationPDF (67 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat vascular endothelium is a cellular monolayer with the organization of a simple squamous epithelium that lines the entire cardiovascular system and constitutes a regulatable barrier between blood and tissues (9, 17). By its location, it is easily accessible to blood-borne drugs or imaging agents, which would target the endothelium itself or be destined to transport to the underlying tissues (13).For a drug or imaging molecule/complex to be targeted to a specific vascular bed, it requires binding to a molecule expressed specifically on the surface of the endothelial cells (EC) in that territory, in either normal or pathological conditions. If uptake is desired, the surface molecule should undergo endocytosis, a term that describes the process of uptake of material into cells (2, 10). If the drug molecule/complex requires delivery to the underlying tissue, it can reach it by either locally manipulating the paracellular pathway or taking advantage of one of the transcellular pathways described (13). The latter are either pores that cut across EC, such as fenestrae, vesiculo vacuolar organelles, and transendothelial channels (specific to the EC in select vascular beds but rather poorly described in terms of components and regulation), or are vesicular in nature (17, 18). The vesicular pathway or transcytosis is common to all epithelia (to which endothelium belongs) and is defined as the process by which large molecules are transported across cellular barriers in membrane-bounded vesicular carriers (21). It encompasses the uptake of the molecule at one endothelial front by endocytosis, transport across the cell via vesicular carriers, and exocytosis at the opposite front. From these, it is readily clear that endothelial endocytosis is one of the critical steps to be reckoned with in the rational design of drug targeting.Endocytosis can occur via diverse mechanisms, which could be divided into two classes: phagocytosis and pinocytosis (reviewed in Refs. 2, 5, and 10). Phagocytosis (in Greek "to eat") refers to internalization of particulates and occurs rarely in EC. Pinocytosis (in Greek "to drink") defines the internalization of soluble molecules as bulk or via interactions with their surface receptors. To date, there are several internalization mechanisms that have been described to participate in pinocytosis: clathrin-mediated uptake (CME), caveolae-mediated uptake (CavME), clathrin- and caveolae-independent internalization (CLIC), and macropinocytosis (occurs rarely in quiescent endothelium in situ, if ever). There are several clathrin- and caveolae-independent uptake pathways or CLIC pathways (5) with respect to their dependence on dynamin, a large GTPase involved in the fission of vesicles from the plasma membrane (8). One pathway is dynamin independent (CLIC) (5), has the ability to internalize large molecular weight ligands, and has been shown to mediate the uptake of glycosylphosphatidylinositol-linked proteins (4, 16). Another pathway is dynamin dependent (CLIC-d) and was described for the IL-2β receptor in immune cells (6). Both these pathways depend on membrane cholesterol and on the integrity of membrane microdomains called lipid rafts.In EC, besides CME and CavME, CLIC was shown to operate for the internalization of proteoglycans and bound growth factors such as FGF-2 (20). Another nonclathrin noncaveolar pathway has been shown to mediate the transport of IgG via the Fc receptor (1, 19). It is not clear whether this pathway is novel or not as no CLIC or CLIC-d markers have been used. A clathrin- and caveolin-1-independent pathway was reported in the case of platelet/endothelial cell adhesion molecule-1 (PECAM-1) constitutive endocytosis and recycling (7), but a formal investigation of its nature was not done.In past work (11, 12, 14, 15), the authors of the report from Muro et al., the current article in focus (Ref. 13a, see p. L809 in this issue), described a novel endocytosis pathway in EC that they called the "cell adhesion molecule-mediated endocytosis pathway" (CAM-ME). The salient features of this pathway are:1) It is induced by cross-linking of either adhesion molecules ICAM-1 (CD54) or PECAM-1 (CD31) by multivalent ligands (i.e., nanocarriers coated with antibodies). The ligands have to be multimeric and within certain sizes (i.e., 100–300 nm) in order for endocytosis to be initiated. Directly labeled "monomeric" antibodies against either PECAM-1 or ICAM-1 did not induce internalization, although a basal internalization rate exists for each of these adhesion molecules (3, 7). There seems to be no correspondence between the surface density of either ICAM-1 or PECAM-1 and the rate of internalization.2) The internalization does not depend on either CME (i.e., no colocalization with clathrin, endocytosis not inhibited by cytosol acidification or monodansyl cadaverine) or CavME (i.e., no colocalization with caveolin-1 or cholera toxin B, no inhibition of uptake by filipin and genistein).3) For endocytosis to occur, there is a requirement for the activation of dynamin-2 obviated by the inhibitory effect of dominant negative dynamin-2 K44A mutants.4) Inhibitors (Y-27632) of ROCK (Rho kinase) lower the uptake of clustered ICAM-1, suggesting that the activation of RhoA small GTPase is necessary. RhoA activates NHE1 (15a) and also induces cytoskeletal rearrangements and formation of stress fibers. Actin polymerization is required (i.e., uptake inhibited by latrunculin A and cytochalasin D that sequester monomeric actin or cap short actin filaments, respectively). There is no actin cup formation as in the case of phagocytosis and macropinocytosis.5) Pharmacological inhibition of Src by radicicol or PKC inhibition by either bisindolylmaleimide I or by H7 lowered the uptake of nanocarriers coated with either anti-ICAM-1 or anti-PECAM-1.6) Nocodazole disruption of microtubules or phosphatidylinositol 3-kinase inhibition by wortmannin have no effect on CAM-ME, which add to the differences with micropinocytosis.By these features, the CAM-ME closely resembles CLIC-d described by Lamaze et al. (6) described for IL-2 receptor in immune cells with the difference that CAM-ME is induced, whereas CLIC-d seems to be constitutive. Another point is that CLIC-d seems to depend on lipid rafts, whereas CAM-ME does not (i.e., not inhibited by filipin). A formal possibility still exists that a constitutive pathway such as CLIC-d could be entered by a different receptor upon activation by large multimeric ligands (that signal ligand size, perhaps). The assessment of the colocalization of IL-2 receptor with ICAM-1 or PECAM-1 cross-linked by antibody-coated nanocarriers should resolve this matter.Upon endocytosis, the cross-linked ICAM-1 or PECAM-1 form endosomes that will fuse in ∼30–60 min to the early endosome antigen (EEA)-1 containing early endosomes. From here, ICAM-1 is segregated from the nanocarriers and recycled to the cell surface via rab11-sorting endosomes, whereas the nanocarriers are transported to the lysosomes.The work by Muro et al. (13a) reported in the current article in focus clearly furthers our knowledge of the molecular requirements for the CAM-ME as well as the endocytic trafficking of the internalized ligands. Upon clustering by multivalent ligands as an initiating step, ICAM-1 colocalizes and associates with Na+/H+ exchanger ion channel NHE1. The activity of NHE1 is required for endocytosis of liganded ICAM-1 but not for clustering as shown by both NHE1 knockdown by small interfering RNA (siRNA) as well as pharmacological inhibition by amiloride and EIPA (a more potent derivative of amiloride). In light of specificity problems inherent with most pharmacological inhibitors, the siRNA experiment is most convincing, although it is not clear whether several individual siRNA (preferable) or a mixture of prescreened siRNA were used to demonstrate the effect. The endocytosis step also depends on Ca2+ entry and calmodulin (previously demonstrated to bind NHE1) as shown by pharmacological inhibitors such as BAPTA and thapsigargin. An interesting question would be to see what is the mechanism of Ca2+ entry (i.e., transient receptor potential cation channels?) involved in this process.After endocytosis to an NHE1-positive, poorly described, early compartment, ICAM-1 and the ligand travel to the EEA-1-positive classic early endosomes. Here, ICAM-1 dissociates from the ligand presumably due to the low pH and is sorted to the rab11-positive sorting endosomes from where it is recycled to the cell surface. The multimeric ligands (in this case, the antibody-coated nanocarriers) are transported to the lysosomes for degradation.Another important point in this paper is the discovery of a "monensin switch" by which the fate of the nanocarriers can be modulated to increase their lifetime within the endothelium. The authors (13a) report that monensin prevents the transport of the nanocarriers to the lysosomes. Early and recycling endosome acidification is regulated in part by Na+/H+ exchanger NHE6. A possible explanation for the effect is that monensin increases the activity of NHE6, creating the conditions of a gain of function situation. The fact that NHE6 is involved is demonstrated by a loss of function experiment achieved by the NHE6 siRNA knockdown, which prevents the transport of nanocarriers to the lysosomes. Another loss of function experiment is based on the finding that PKC activates intracellular NHE channels. PKC inhibition by H7 results in a lack of NHE activation and activation of transport correlating the siRNA experiment, notwithstanding the much broader serine/threonine kinase inhibition activity of H7 at the concentration used. In consequence, upon monensin treatment, the pH of the early endosomes increases, resulting in continuous association of ICAM-1 with the nanocarriers and the transport of the whole complex to the recycling endosomes and from there to the cell surface. The authors examine this hypothesis but conclude that there is more to the monensin/endosomal acidification effect since cloroquine, another inhibitor of endosomal acidification, does not prevent the transport of nanocarriers to the lysosomes. They propose that the unrepressed Na+/H+ exchange by monensin may secondarily lead to Cl− influx to the endosomal lumen to maintain ion balance, accompanied by H2O influx and endosomal engorgement favoring exocytosis. All in all, the net effect of monensin treatment is the extended lifetime of the drugs administered via nanocarriers, which may improve drug efficacy.The precise mechanism of CAM-ME is far from being clear as is the nature of the early endosomes involved in uptake and the intermediate relays, if any, to the classic EEA1-positive early endosomes. Many questions remain with respect to its relationship to other endocytosis pathways in EC and whether cell-type variations exist or not. A hurdle in all this might be the lack of a standardized nomenclature and criteria for each pathway due to insufficient data on each of them. A systematic comparison of the pathways (i.e., comprehensive use of markers) so far described should shed light on this. The future looks bright as better and more specific tools are built and more data become available.AUTHOR NOTESAddress for reprint requests and other correspondence: R. V. Stan, Dartmouth Medical School, Dept. of Pathology, HB 7600, Borwell 502W, 1 Medical Center Dr., Hanover, NH 92093-0651 (e-mail: Radu.V.Stan@Dartmouth.edu) Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1 Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, and Anderson CL. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197: 315–322, 2003.Crossref | PubMed | ISI | Google Scholar2 Conner SD and Schmid SL. Regulated portals of entry into the cell. Nature 422: 37–44, 2003.Crossref | PubMed | ISI | Google Scholar3 Danilov SM, Gavrilyuk VD, Franke FE, Pauls K, Harshaw DW, McDonald TD, Miletich DJ, and Muzykantov VR. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280: L1335–L1347, 2001.Link | ISI | Google Scholar4 Kirkham M, Fujita A, Chadda R, Nixon SJ, Kurzchalia TV, Sharma DK, Pagano RE, Hancock JF, Mayor S, and Parton RG. Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. J Cell Biol 168: 465–476, 2005.Crossref | PubMed | ISI | Google Scholar5 Kirkham M and Parton RG. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 1745: 273–286, 2005.Crossref | PubMed | ISI | Google Scholar6 Lamaze C, Dujeancourt A, Baba T, Lo CG, Benmerah A, and Dautry-Varsat A. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell 7: 661–671, 2001.Crossref | PubMed | ISI | Google Scholar7 Mamdouh Z, Chen X, Pierini LM, Maxfield FR, and Muller WA. Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 421: 748–753, 2003.Crossref | PubMed | ISI | Google Scholar8 McNiven MA. Dynamin in disease. Nat Genet 37: 215–216, 2005.Crossref | PubMed | ISI | Google Scholar9 Mehta D, Bhattacharya J, Matthay MA, and Malik AB. Integrated control of lung fluid balance. Am J Physiol Lung Cell Mol Physiol 287: L1081–L1090, 2004.Link | ISI | Google Scholar10 Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12: 575–625, 1996.Crossref | PubMed | ISI | Google Scholar11 Muro S, Cui X, Gajewski C, Murciano JC, Muzykantov VR, and Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol 285: C1339–C1347, 2003.Link | ISI | Google Scholar12 Muro S, Gajewski C, Koval M, and Muzykantov VR. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 105: 650–658, 2005.Crossref | PubMed | ISI | Google Scholar13 Muro S, Koval M, and Muzykantov V. Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol 2: 281–299, 2004.Crossref | PubMed | Google Scholar13a Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov VR, and Koval M. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol 290: L809–L817, 2006.Link | ISI | Google Scholar14 Muro S, Muzykantov VR, and Murciano JC. Characterization of endothelial internalization and targeting of antibody-enzyme conjugates in cell cultures and in laboratory animals. Methods Mol Biol 283: 21–36, 2004.PubMed | Google Scholar15 Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, and Koval M. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 116: 1599–1609, 2003.Crossref | PubMed | ISI | Google Scholar15a Putney LK, Denker SP, and Barber DL. The changing face of the Na+/H+ exchanger, NHE1: structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 42: 527–522, 2002.Crossref | PubMed | ISI | Google Scholar16 Sabharanjak S, Sharma P, Parton RG, and Mayor S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell 2: 411–423, 2002.Crossref | PubMed | ISI | Google Scholar17 Stan RV. Channels across endothelial cells. In: Cell-Cell Channels, edited by Baluska F, Volkmann D, and Barlow PW. Georgetown, TX: Landes Bioscience. In press.Google Scholar18 Stan RV. Structure and function of endothelial caveolae. Microsc Res Tech 57: 350–364, 2002.Crossref | PubMed | ISI | Google Scholar19 Takizawa T, Anderson CL, and Robinson JM. A novel FcγR-defined, IgG-containing organelle in placental endothelium. J Immunol 175: 2331–2339, 2005.Crossref | PubMed | ISI | Google Scholar20 Tkachenko E, Lutgens E, Stan RV, and Simons M. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci 117: 3189–3199, 2004.Crossref | PubMed | ISI | Google Scholar21 Tuma PL and Hubbard AL. Transcytosis: crossing cellular barriers. Physiol Rev 83: 871–932, 2003.Link | ISI | Google Scholar Cited ByClathrin-Mediated Albumin Clearance in Alveolar Epithelial Cells of Murine Precision-Cut Lung Slices31 January 2023 | International Journal of Molecular Sciences, Vol. 24, No. 3Dengue virus non-structural protein 1 activates the p38 MAPK pathway to decrease barrier integrity in primary human endothelial cellsJournal of General Virology, Vol. 101, No. 5Ultrastructural analysis of submacular choriocapillaris and its transport systems in AMD and aged control eyesExperimental Eye Research, Vol. 181Plasma Membrane as a Semipermeable Barrier14 April 2016αKlotho deficiency in acute kidney injury contributes to lung damagePriya Ravikumar, Liping Li, Jianfeng Ye, Mingjun Shi, Masatomo Taniguchi, Jianning Zhang, Makoto Kuro-o, Ming Chang Hu, Orson W. Moe, and Connie C. W. Hsia1 April 2016 | Journal of Applied Physiology, Vol. 120, No. 7PI5P Triggers ICAM-1 Degradation in Shigella Infected Cells, Thus Dampening Immune Cell RecruitmentCell Reports, Vol. 14, No. 4A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders11 January 2016 | Molecular Pharmaceutics, Vol. 13, No. 2Specific Binding, Uptake, and Transport of ICAM-1-Targeted Nanocarriers Across Endothelial and Subendothelial Cell Components of the Blood–Brain Barrier21 February 2014 | Pharmaceutical Research, Vol. 31, No. 7Challenges in design and characterization of ligand-targeted drug delivery systemsJournal of Controlled Release, Vol. 164, No. 2Targeted Delivery to the Pulmonary Endothelium23 August 2012Intercellular Adhesion Molecule 1 Engagement Modulates Sphingomyelinase and Ceramide, Supporting Uptake of Drug Carriers by the Vascular EndotheliumArteriosclerosis, Thrombosis, and Vascular Biology, Vol. 32, No. 5Uptake of Single-Walled Carbon Nanotubes Conjugated with DNA by Microvascular Endothelial CellsJournal of Nanotechnology, Vol. 2012Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review)28 October 2010 | Molecular Membrane Biology, Vol. 27, No. 7Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review)8 July 2010 | Molecular Membrane Biology, Vol. 27, No. 4-6Control of Endothelial Targeting and Intracellular Delivery of Therapeutic Enzymes by Modulating the Size and Shape of ICAM-1-targeted CarriersMolecular Therapy, Vol. 16, No. 8RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1Blood, Vol. 111, No. 6 More from this issue > Volume 290Issue 5May 2006Pages L806-L808 Copyright & PermissionsCopyright © 2006 the American Physiological Societyhttps://doi.org/10.1152/ajplung.00533.2005PubMed16603594History Published online 1 May 2006 Published in print 1 May 2006 Metrics Downloaded 972 times 24 CITATIONS 24 Total citations 1 Recent citation 3.97 Field Citation Ratio 0.56 Relative Citation Ratio publications24supporting1mentioning22contrasting0Smart Citations241220Citing PublicationsSupportingMentioningContrastingView CitationsSee how this article has been cited at scite.aiscite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.